Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus extension study after core trial CRAD001H2304 in de novo liver transplant recipients
NL-OMON34870Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus and tacrolimus in Renal Insufficiency (RI) (3 arms), sponsored by Novartis. Primary endpoints: Renal function, Composite efficacy endpoint of graft loss or death and 2 more. Started Sep 2010; status: active, not recruiting.
02
Drugs
everolimustacrolimus
03
Conditions
Renal Insufficiency (RI)
Beyond the preview
Go deeper on NL-OMON34870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34870.